Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12 GBX | -5.88% | +45.45% | -45.45% |
Apr. 19 | Redx Pharma shareholders approve AIM delisting plans | AN |
Apr. 19 | Redx Pharma Gets Shareholder Approval for Delisting from AIM | MT |
Sales 2024 * | 12.5M 15.46M | Sales 2025 * | - | Capitalization | 46.68M 57.74M |
---|---|---|---|---|---|
Net income 2024 * | -26M -32.16M | Net income 2025 * | -49M -60.61M | EV / Sales 2024 * | 3.35 x |
Net cash position 2024 * | 4.81M 5.95M | Net Debt 2025 * | 39.12M 48.39M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.79
x | P/E ratio 2025 * |
-0.95
x | Employees | 101 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.77% |
Latest transcript on Redx Pharma Plc
1 day | -5.88% | ||
1 week | +45.45% | ||
Current month | -35.14% | ||
1 month | -41.46% | ||
3 months | -41.46% | ||
6 months | -53.85% | ||
Current year | -45.45% |
Managers | Title | Age | Since |
---|---|---|---|
Lisa Anson
CEO | Chief Executive Officer | - | 18-05-31 |
Peter J. Collum
DFI | Director of Finance/CFO | - | 21-05-04 |
Chief Operating Officer | 46 | 18-11-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Scott
BRD | Director/Board Member | 70 | 22-01-26 |
Joseph Anderson
BRD | Director/Board Member | 65 | 23-09-05 |
Peter Presland
BRD | Director/Board Member | 75 | 17-11-02 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 12 | -5.88% | 582,013 |
24-04-18 | 12.75 | -5.56% | 839,827 |
24-04-17 | 13.5 | +22.73% | 1,049,536 |
24-04-16 | 11 | +22.22% | 779,645 |
24-04-15 | 9 | +9.09% | 757,519 |
Delayed Quote London S.E., April 19, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-45.45% | 57.94M | |
-3.10% | 102B | |
+2.11% | 96.37B | |
-1.80% | 21.37B | |
-17.75% | 20.92B | |
-6.91% | 18.64B | |
-42.00% | 16.4B | |
-28.19% | 13.53B | |
+0.18% | 13.28B | |
+19.90% | 10.85B |
- Stock Market
- Equities
- REDX Stock